AT-101, which binds to BCL-2 and BCL-XL at 300–400 nM, also failed to reduce B-ALL cell viability alone or in combination with trametinib (Supplementary Table S3; Supplementary Figure S3b). The gene discussed is BCL2L1; the disease is precursor B-cell acute lymphoblastic leukemia.